23 Empagliflozin was additionally associated with a 14% lower rate of a pre-specified secondary endpoint of new-onset diabetes in the EMPEROR-Reduced trial, 18 but was assessed only in participants with pre-diabetes at baseline and did not reach statistical significance.
← all excerpts
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
1
—
—